NLRP3 and multiple sclerosis: So far, several agents targeting on the inhibition of the NLRP3 inflammasome have been demonstrated to be effective in the treatment of multiple sclerosis or shown on the mice models of multiple sclerosis (experimental autoimmune encephalomyelitis, EAE).